Find Reports

Select Report Type

Reimbursement Review

Displaying 626 - 650 of 1258

Please scroll or swipe to the right to view the full content.

Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
Entyvio	Vedolizumab	cdr_SR0421_Entyvio.pdf SR0421_cdr_complete_Entyvio_Nov-2-15_e.pdf SR0421_Entyvio_CL_Report.pdf SR0421_Entyvio_PE_Report.pdf SR0421_Entyvio_PI_Submissions.pdf	Ulcerative colitis	List with clinical criteria and/or conditions	Complete	Feb 20, 2015	Oct 28, 2015	SR0421-000
Ofev	Nintedanib	cdr_SR0426_Ofev.pdf SR0426_Ofev_Oct-19-15.pdf SR0426_Ofev_CL_Report.pdf SR0426_Ofev_PE_Report.pdf SR0426_Ofev_PI_Submissions.pdf	Idiopathic pulmonary fibrosis	List with clinical criteria and/or conditions	Complete	Apr 23, 2015	Oct 15, 2015	SR0426-000
Jardiance	Empagliflozin	Recommendation and Reasons: Updated Submission Status Report Recommendation and Reasons: Original Clinical Report Pharmacoeconomic Report Patient Group Input Submissions	Diabetes mellitus, type 2	List with clinical criteria and/or conditions	Complete	Apr 23, 2015	Oct 15, 2015	SR0427-000
Iclusig	Ponatinib	pcodr_provfund_iclusig_cml-all.pdf pcodr_ponatinib_iclusig_cml-all_fn_rec.pdf pcodr_ponatinib_iclusig_cml-all_fn_cgr.pdf pcodr_ponatinib_iclusig_cml-all_fn_egr.pdf pcodr_ponatinib_iclusig_cml_all_in_rec.pdf pcodr_ponatinib_iclusig_cml-all_pagfdk.pdf pcodr_ponatinib_iclusig_cml-all_fdk_ariad.pdf	Chronic Myeloid Leukemia/ Acute Lymphoblastic Leukemia	Reimburse with clinical criteria and/or conditions	Complete	Mar 13, 2015	Oct 1, 2015	PC0056 -000
Constella	Linaclotide	cdr_SR0409_Constella.pdf SR0409_Constella_ Sept_25-15.pdf SR0409_Constella_CL_Report.pdf SR0409_Constella_PE_Report.pdf SR0409_Constella_PI_Submissions.pdf	Irritable bowel syndrome with constipation	Do not list	Complete	Dec 17, 2014	Sep 23, 2015	SR0409-000
Daklinza	Daclatasvir	cdr_SR0417_Daklinza.pdf SR0417_cdr_complete_Daklinza_Sept-23-15_e.pdf SR0417_Daklinza_CL_Report.pdf SR0417_Daklinza_PE_Report.pdf SR0417 Daklinza_PI_Submissions.pdf	Hepatitis C, Chronic	List with clinical criteria and/or conditions	Complete	Feb 13, 2015	Sep 21, 2015	SR0417-000
Prolia	Denosumab (Drug Plan Submission)	cdr_SR0414_Prolia-Men.pdf SR0414_cdr_complete_Prolia-Men_Sept-21-15-e.pdf SR0414_ProliaMen_CL_Report.pdf SR0414_ProliaMen_PE_Report.pdf SR0414_ProliaMen_PI_Submissions.pdf	Osteoporosis, men	List with clinical criteria and/or conditions	Complete	Mar 10, 2015	Sep 21, 2015	SR0414-000
Incruse Ellipta	Umeclidinium	cdr_SR0422_Incruse-Ellipta.pdf SR0422_Incruse_Ellipta_Sept-22-15.pdf SR0422_Incruse_Ellipta_CL_Report.pdf SR0422_Incruse_Ellipta_PE_Report.pdf	Chronic obstructive pulmonary disease	List with criteria/condition	Complete	Mar 4, 2015	Sep 18, 2015	SR0422-000
Duaklir Genuair	Aclidinium bromide/formoterol fumarate dihydrate	cdr_SR0423_Duaklir_Genuair.pdf SR0423_Duaklir_Genuair_Sept-22-15-e.pdf SR0423_DuaklirGenuair_PI.pdf SR0423_DuaklirGenuair_FDC_Report.pdf	Chronic obstructive pulmonary disease	List with clinical criteria and/or conditions	Complete	Apr 1, 2015	Sep 18, 2015	SR0423-000
Zydelig	Idelalisib	pcodr-provfund_idelalisib-zydelig-cll.pdf pcodr_idelalisib_zydelig_cll_fn_rec.pdf pcodr_idelalisib_zydelig_cll_fn_cgr.pdf pcodr_idelalisib_zydelig_cll_fn_egr.pdf Idelalisib Initial Recommendation_ 2015-07-30_AC_30July2015_FinalPost.pdf pcodr_idelalisib_zydelig_cll_pagfdk.pdf pcodr_idelalisib_zydelig_cll_API.pdf pcodr_idelalisib_zydelig_cll_ptfdk_lc.pdf pcodr_idelalisib_zydelig_cll_coi_lc.pdf pcodr_idelalisib_zydelig_cll_ptfdk_cllpag_llsc.pdf pcodr_idelalisib_zydelig_cll_coi_cllpag.pdf pcodr_idelalisib_zydelig_cll_coi_llsc.pdf	Chronic lymphocytic leukemia	Reimburse with clinical criteria and/or conditions	Complete	Apr 7, 2015	Aug 18, 2015	PC0057-000
Otezla	Apremilast	cdr_SR0400_Otezla.pdf SR0400-Otezla-Aug-10-15-e.pdf SR0400_Otezla_CL_Report.pdf SR0400_Otezla_PE_Report.pdf	Plaque psoriasis	Do not list	Complete	Oct 8, 2014	Jul 22, 2015	SR0400-000
Avastin (with capecitabine)	Bevacizumab	pcodr_provfund_avastin-capecitabine_mcrc.pdf pcodr_avastin_capecitabine_mcrc_fn_rec.pdf pcodr_avastin_capecitabine_mcrc_fn_cgr.pdf pcodr_avastin_capecitabine_mcrc_fn_egr.pdf pcodr_avastin_capecitabine_mcrc_in_rec.pdf pcodr_avastin_capecitabine_mcrc_pagfdk.pdf pcodr_avastin_capecitabine_mcrc_fdk_roche.pdf pcodr_avastin_capecitabine_mcrc_ptfdk_ccac.pdf pcodr_avastin_capecitabine_mcrc_coi_ccac.pdf	Metastatic Colorectal Cancer	Reimburse with clinical criteria and/or conditions	Complete	Feb 18, 2015	Jul 21, 2015	PC0055-000
Xalkori	Crizotinib	pcodr-provfund_xalkori_nsclc1stline.pdf pcodr_xalkori_1stln_nsclc_fn_rec.pdf pcodr_xalkori_1stln_nsclc_fn_cgr.pdf pcodr_xalkori_1stln_nsclc_fn_egr.pdf pcodr_xalkori_1stln_nsclc_in_rec.pdf pcodr_xalkori_1stln_nsclc_pagfdk.pdf pcodr_xalkori_1stln_nsclc_fdk_pfizer.pdf pcodr_xalkori_1stln_nsclc_coi_ola.pdf pcodr_xalkori_1stln_nsclc_coi_lcc.pdf	First Line ALK Positive Advanced NSCLC	Reimburse with clinical criteria and/or conditions	Complete	Feb 17, 2015	Jul 21, 2015	PC0054-000
Tafinlar & Mekinist in combo	Dabrafenib & Trametinib in combo	pcodr-provfund_tafinlarmekinist_melanoma.pdf pcodr_tafinlar_mekinist_metmelanoma_fn_rec.pdf pcodr_tafinlar_mekinist_metmelanoma_fn_cgr.pdf pcodr_tafinlar_mekinist_metmelanoma_fn_egr.pdf pcodr_tafinlar_mekinist_metmelanoma_in_rec.pdf pcodr_tafinlar_mekinist_metmelanoma_pagfdk.pdf pcodr_tafinlar_mekinist_metmelanoma_fdk_gsm.pdf pcodr_tafinlar_mekinist_metmelanoma_ptfdk_mnc.pdf pcodr_tafinlar_mekinist_metmelanoma_ptfdk_sysf.pdf pcodr_tafinlar_mekinist_metmelanoma_coi_mnc.pdf pcodr_tafinlar_mekinist_metmelanoma_coi_sysf.pdf	Metastatic Melanoma	Reimburse with clinical criteria and/or conditions	Complete	Feb 13, 2015	Jul 21, 2015	PC0053-000
Spiriva Respimat	Tiotropium bromide	SR0412 Spiriva Respimat.pdf SR0412-complete-Spiriva-Respimat-July-20-15-e.pdf SR0412_SpirivaRespimat_CL_Report.pdf SR0412_SpirivaRespimat_PE_Report.pdf SR0412_SpirivaRespimat_PI_Submissions.pdf	Chronic obstructive pulmonary disease	List with clinical criteria and/or conditions	Complete	Dec 23, 2014	Jul 16, 2015	SR0412-000
Nexavar	Sorafenib	pcodr-provfund_sorafenib_nexavar_dtc.pdf pcodr_sorafenib_nexavar_dtc_fn_rec.pdf pcodr_sorafenib_nexavar_dtc_fn_cgr.pdf pcodr_sorafenib_nexavar_dtc_fn_egr.pdf pcodr_sorafenib_nexavar_dtc_in_rec.pdf pcodr_sorafenib_nexavar_dtc_pagfdk.pdf pcodr_sorafenib_nexavar_dtc_fdk_bayer.pdf pcodr_sorafenib_nexavar_dtc_ptfdk_tcc.pdf pcodr_sorafenib_nexavar_dtc_coi_tcc.pdf	Metastatic Progressive Differentiated Thyroid Carcinoma (DTC)	Do not reimburse	Complete	Dec 19, 2014	Jul 16, 2015	PC0049-000
Perjeta or Perjeta-Herceptin Combo Pack	Pertuzumab	pcodr-provfund_pertuzumab_perjeta_nbc.pdf pcodr_pertuzumab_perjeta_nbc_fn_rec.pdf pcodr_pertuzumab_perjeta_nbc_fn_cgr.pdf pcodr_pertuzumab_perjeta_nbc_fn_egr.pdf pcodr_pertuzumab_perjeta_nbc_in_rec.pdf pcodr_pertuzumab_perjeta_nbc_pagfdk.pdf pcodr_pertuzumab_perjeta_nbc_fdk_roche.pdf pcodr_pertuzumab_perjeta_nbc_ptfdk_cbcn.pdf pcodr_pertuzumab_perjeta_nbc_coi_cbcn.pdf	Neoadjuvant Breast Cancer	Do not reimburse	Complete	Dec 19, 2014	Jul 16, 2015	PC0050-000
Stivarga Resubmission (CRC)	Regorafenib	pcodr-provfund_regorafenib_stivarga-resub_mcrc.pdf pcodr_regorafenib_stivarga_resub_mcrc_fn_rec.pdf pcodr_regorafenib_stivarga_resub_mcrc_fn_cgr.pdf pcodr_regorafenib_stivarga_resub_mcrc_fn_egr.pdf pcodr_regorafenib_stivarga_resub_mcrc_in_rec.pdf pcodr_regorafenib_stivarga_resub_mcrc_pagfdk.pdf pcodr_regorafenib_stivarga_resub_mcrc_fdk_bayer.pdf pcodr_regorafenib_stivarga_resub_mcrc_ptfdk_ccac.pdf pcodr_regorafenib_stivarga_resub_mcrc_coi_ccac.pdf	Metastatic Colorectal Cancer	Do not reimburse	Complete	Dec 19, 2014	Jul 16, 2015	PC0046-000
Proleukin	Aldesleukin (IL-2)	pcodr-provfund_proleukin-melanoma.pdf pcodr_aldesleukin_proleukin_fn_rec.pdf pcodr_adesleukin_proleukin_fn_cgr.pdf pcodr_adesleukin_proleukin_fn_egr.pdf pcodr-aldesleukin-proleukin-in-transit-melanoma-in-rec.pdf pcodr_adesleukin_proleukin_pagfdk_0.pdf pcodr_adesleukin_proleukin_fdk_novartis.pdf pcodr_adesleukin_proleukin_ptfdk_mnc.pdf pcodr_adesleukin_proleukin_coi_mnc.pdf pcodr_adesleukin_proleukin_coi_sysf.pdf	In-transit Melanoma	Reimburse	Complete	Jan 30, 2015	Jun 22, 2015	PC0051-000
Sylvant	Siltuximab	pcodr_provfund_sylvant_mcd.pdf pcodr_siltuximab_sylvant_mcd_fn_rec.pdf pcodr_siltuximab_sylvant_mcd_fn_cgr.pdf pcodr_siltuximab_sylvant_mcd_fn_egr.pdf pcodr_siltuximab_sylvant_mcd_in_rec.pdf pcodr_siltuximab_sylvant_mcd_pagfdk.pdf pcodr_siltuximab_sylvant_mcd_fdk_janssen.pdf pcodr_siltuximab_sylvant_mcd_coi_cord.pdf	Multicentric Castleman's disease (MCD)	Reimburse with clinical criteria and/or conditions	Complete	Jan 30, 2015	Jun 22, 2015	PC0052-000
Xtandi	Enzalutamide	pcodr-provfund_xtandi_mcrpc1stline.pdf pcodr_enzalutamide_xtandi_1stln_mcrpc_fn_rec.pdf pcodr_enzalutamide_xtandi_1stln_mcrpc_fn_cgr.pdf pcodr_enzalutamide_xtandi_1stln_mcrpc_fn_egr.pdf pcodr_enzalutamide_xtandi_1stln_mcrcp_in_rec.pdf pcodr_enzalutamide_xtandi_1stln_mcrpc_pagfdk.pdf pcodr_enzalutamide_xtandi_1stln_mcrpc_fdbk_astellas.pdf pcodr_enzalutamide_xtandi_1stln_mcrpc_ptfdk_pcc.pdf pcodr_enzalutamide_xtandi_1stln_mcrpc_coi_pcc.pdf	First Line Metastatic Castration-Resistant Prostate Cancer	Reimburse with clinical criteria and/or conditions	Complete	Oct 2, 2014	Jun 22, 2015	PC0044-000
Lemtrada	Alemtuzumab	cdr_SR0405_Lemtrada.pdf cdr-complete-SR0405-Lemtrada-June-22-2015.pdf SR0405_Lemtrada_RRMS_CL_Report.pdf SR0405_Lemtrada_RRMS_PE_Report.pdf SR0405 Lemtrada_RRMS_PI_Submissions.pdf	Multiple sclerosis, relapsing-remitting	List with criteria/condition	Complete	Nov 27, 2014	Jun 18, 2015	SR0405-000
Holkira Pak	Ombitasvir/paritaprevir/ritonavir and dasabuvir	SR0406 Holkira Pak.pdf SR0406-Holkira-Pak-July-22-15-e.pdf SR0406_HolkiraPak_CL_Report.pdf SR0406_HolkiraPak_PE_Report.pdf SR0406_HolkiraPak_PI_Submissions.pdf	Hepatitis C, chronic	List with clinical criteria and/or conditions	Complete	Dec 3, 2014	Jun 18, 2015	SR0406-000
Simbrinza	Brinzolamide / brimonidine	cdr_SR0403_Simbrinza.pdf cdr_complete_SR0403_Simbrinza_June-19_2015.pdf SR0403_Simbrinza_PI_Submissions.pdf SR0403_Simbrinza_FDC_Review_Report.pdf	Glaucoma and ocular hypertension	List	Complete	Nov 3, 2014	Jun 17, 2015	SR0403-000
Dymista	Azelastine HCl and fluticasone propionate	cdr_SR0408_Dymista.pdf cdr_complete_SR0408_Dymista_June-19-2015.pdf SR0408_Dymista_CL_Report.pdf SR0408_Dymista_PE_Report.pdf SR0408_Dymista_PI_Submissions.pdf	Seasonal allergic rhinitis	Do not list	Complete	Dec 9, 2014	Jun 17, 2015	SR0408-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 576 - 589 of 589

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 111 of 111

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 40 of 40

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 626 - 650 of 2093

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
Hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer	Final Report	Mar 8, 2023	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0018-000
Automatic Stop Orders for Opioids	Automatic Stop Orders for Opioids	Mar 8, 2023	Health Technology Review	Rapid Review	Completed	RC1473-000
Point-of-Care Tests for Pancreatitis	Point-of-Care Tests for Pancreatitis	Mar 6, 2023	Horizon Scan	Health Technology Update	Completed	EN0045-000
Dental Sealants for the Prevention of Dental Caries	Dental Sealants for the Prevention of Dental Caries	Mar 1, 2023	Health Technology Review	Rapid Review	Completed	RC1471-000
mepolizumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Feb 27, 2023	Reimbursement Review		Complete	SR0735-000
guselkumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Feb 27, 2023	Reimbursement Review		Complete	SR0733-000
edaravone	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Rétroaction des intervenants sur la recommandations provisoire	Feb 24, 2023	Reimbursement Review		Complete	SR0727-000
Nabilone for the Treatment of Post-Traumatic Stress Disorder: A 2023 Update	Nabilone for the Treatment of Post-Traumatic Stress Disorder: A 2023 Update	Feb 24, 2023	Health Technology Review	Summary with Critical Appraisal	Completed	RC1472-000
dalbavancin	Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Stakeholder Feedback on Draft Recommendation	Feb 23, 2023	Reimbursement Review		Complete	SR0728-000
pitolisant hydrochloride	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Feb 22, 2023	Reimbursement Review		Complete	SR0715-000
ozanimod	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Feb 22, 2023	Reimbursement Review		Complete	SR0714-000
Bladder Scanners in Personal Care Homes	Bladder Scanners in Personal Care Homes	Feb 21, 2023	Health Technology Review	Rapid Review	Completed	RC1470-000
Wastewater Surveillance for Communicable Disease	Wastewater Surveillance for Communicable Disease	Feb 21, 2023	Horizon Scan	Emerging Health Technologies	Completed	EH0114-000
CADTH Pharmaceutical Reviews Update — Issue 34		Feb 16, 2023	Reimbursement Review	Pharmaceutical Review Update
Sotrovimab for the Treatment of COVID-19	Sotrovimab for the Treatment of COVID-19	Feb 14, 2023	Health Technology Review	Rapid Review	Completed	RC1468-000
tafasitamab	Memorandum report to CADTH Response to the Procedural Review Panel’s Memorandum Report Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Feb 10, 2023	Reimbursement Review		Complete	PC0266-000
Tenecteplase for Acute Ischemic Stroke	Tenecteplase for Acute Ischemic Stroke	Feb 9, 2023	Health Technology Review	Rapid Review	Completed	RC1469-000
cariprazine	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Feb 8, 2023	Reimbursement Review		Complete	SR0718-000
entrectinib	Recommendation and Reasons Clinical, Pharmacoeconomic, Ethics, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Feb 8, 2023	Reimbursement Review		Complete	PC0278-000
tezepelumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Feb 7, 2023	Reimbursement Review		Complete	SR0731-000
pembrolizumab	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Feb 7, 2023	Reimbursement Review		Complete	PC0286-000
Melanoma	Final Report	Feb 6, 2023	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0022-000
Differentiated Thyroid Carcinoma	Final Report	Feb 6, 2023	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0021-000
Specialized Clinics and Health Care Professional Resources for Post–COVID-19 Condition in Canada	Specialized Clinics and Health Care Professional Resources for Post–COVID-19 Co…	Feb 6, 2023	Health Technology Review	Environmental Scan	Completed	ES0372-000
lutetium oxodotreotide	Recommendation and Reasons Clinical, Pharmacoeconomic, and Stakeholder Input Combined Report Stakeholder Feedback on Draft Recommendation	Feb 1, 2023	Reimbursement Review		Complete	PC0284-000